REGULUS THERAPEUTICS INC.

(RGLS)
  Report
Delayed Nasdaq  -  04:00 2022-07-06 pm EDT
2.070 USD   +2.99%
06/29REGULUS THERAPEUTICS INC. : REVERSE SPLIT: 1 of 10
FA
06/28Wall Street Set to Open Higher
MT
06/28Top Premarket Decliners
MT
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
06/29/2022 06/30/2022 07/01/2022 07/05/2022 07/06/2022 Date
2.1(c) 2.07(c) 2.07(c) 2.01(c) 2.07(c) Last
206 924 126 527 39 272 172 112 38 442 Volume
+2.94% -1.43% 0.00% -2.90% +2.99% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 - - -
Net income 2022 -27,9 M - -
Net Debt 2022 - - -
P/E ratio 2022 -1,06x
Yield 2022 -
Sales 2023 3,13 M - -
Net income 2023 -36,8 M - -
Net Debt 2023 - - -
P/E ratio 2023 -1,00x
Yield 2023 -
Capitalization 30,2 M 30,2 M -
Capi. / Sales 2022 -
Capi. / Sales 2023 9,67x
Nbr of Employees 25
Free-Float 9,47%
More Financials
Company
Regulus Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing drugs targeting microRNAs to treat diseases. The Company is leveraging its oligonucleotide drug discovery and development to develop a pipeline complemented by a rich intellectual property estate in the microRNA field. The Company’s product lead product candidates include RG-012 and RGLS8429. The Company... 
More about the company
All news about REGULUS THERAPEUTICS INC.
06/29REGULUS THERAPEUTICS INC. : REVERSE SPLIT: 1 of 10
FA
06/28Wall Street Set to Open Higher
MT
06/28Top Premarket Decliners
MT
06/27REGULUS THERAPEUTICS INC. : Material Modification to Rights of Security Holders, Financial..
AQ
06/21Regulus Therapeutics Announces Receipt of FDA Orphan Drug Designation for RGLS8429 for ..
PR
06/21Regulus Therapeutics Announces Receipt of FDA Orphan Drug Designation for RGLS8429 for ..
CI
06/21Regulus Therapeutics Gets FDA Orphan Designation for RGLS8429
DJ
06/13REGULUS THERAPEUTICS INC. : Change in Directors or Principal Officers, Submission of Matte..
AQ
06/13Regulus Reports First Individual Dosed in Early-Stage Single-Ascending Dose Trial of RG..
MT
06/13Regulus Therapeutics Announces First Subject Dosed in Phase 1 Single-Ascending Dose (SA..
PR
06/13Regulus Therapeutics Inc. Announces First Subject Dosed in Phase 1 Single-Ascending Dos..
CI
06/02Regulus Appoints Amin Kamel, Ph.D., as Vice President, DMPK
PR
05/17Regulus Therapeutics to Present at the H.C. Wainwright Global Investment Conference
PR
05/13REGULUS THERAPEUTICS INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION ..
AQ
05/12TRANSCRIPT : Regulus Therapeutics Inc., Q1 2022 Earnings Call, May 12, 2022
CI
More news
News in other languages on REGULUS THERAPEUTICS INC.
06/21Regulus Therapeutics annonce avoir reçu la désignation de médicament orphelin de la FDA..
06/13Regulus annonce que la première personne a reçu une dose dans le cadre d'un essai de ph..
06/13Regulus Therapeutics Inc. Annonce du premier sujet traité dans le cadre de l'essai clin..
05/12Regulus Therapeutics Inc. annonce ses résultats pour le premier trimestre clos le 31 ma..
05/11MISE À JOUR SECTORIELLE : Les actions du secteur de la santé en baisse avant la clôture de..
More news
Analyst Recommendations on REGULUS THERAPEUTICS INC.
More recommendations
Chart REGULUS THERAPEUTICS INC.
Duration : Period :
Regulus Therapeutics Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends REGULUS THERAPEUTICS INC.
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 3
Last Close Price 2,07 $
Average target price 15,00 $
Spread / Average Target 625%
EPS Revisions
Managers and Directors
Joseph P. Hagan President, Chief Executive Officer & Director
Crispina Calsada Chief Financial Officer
Stelios Papadopoulos Chairman
Denis Drygin Chief Scientific Officer
David Baltimore Independent Director
Sector and Competitors
1st jan.Capi. (M$)
REGULUS THERAPEUTICS INC.-34.29%30
GILEAD SCIENCES, INC.-13.61%78 683
VERTEX PHARMACEUTICALS32.59%74 466
REGENERON PHARMACEUTICALS, INC.-5.80%64 098
WUXI APPTEC CO., LTD.-4.67%49 112
BIONTECH SE-37.86%38 932